Patents by Inventor Claire Dugast Darzacq

Claire Dugast Darzacq has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MOLECULAR TARGETS FOR THE TREATMENT OF WOUNDS, IN PARTICULAR CHRONIC WOUNDS
    Publication number: 20190022097
    Abstract: The present invention relates to a therapeutic compound comprising: an agent that inhibits the activity of at least one gene selected from the group consisting of MAF, MEOX2, SIX2 and homologues thereof having at least 50% identity with said genes and/or an agent that enhances the activity of at least one gene selected from the group consisting of CREB5, E2F1, EGR2, HIC1, IRF7, JUN, MYC, SRF, STAT4, TCF4, FOXS1, GLI1, SOX9 and homologues thereof having at least 50% identity with said gene for use in the treatment of wounds, preferably chronic wounds.
    Type: Application
    Filed: August 6, 2018
    Publication date: January 24, 2019
    Inventors: Claire Dugast-Darzacq, Maïté Noizet, Xavier Darzacq, Beatrice Spiluttini Hebert
  • Molecular targets for the treatment of wounds, in particular chronic wounds
    Patent number: 10071097
    Abstract: The present invention relates to a therapeutic compound comprising: an agent that inhibits the activity of at least one gene selected from the group consisting of MAF, MEOX2, SIX2 and homologs thereof having at least 50% identity with said genes and/or an agent that enhances the activity of at least one gene selected from the group consisting of CREB5, E2F1, EGR2, HIC1, IRF7, JUN, MYC, SRF, STAT4, TCF4, FOXS1, GLI1, SOX9 and homologs thereof having at least 50% identity with said gene for use in the treatment of wounds, preferably chronic wounds.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: September 11, 2018
    Assignees: URGO RECHERCHE INNOVATION ET DEVELOPPEMENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, UNIVERITÉ PARIS DIDEROT—PARIS 7, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), ECOLE NORMALE SUPERIEURE
    Inventors: Claire Dugast-Darzacq, Maïté Noizet, Xavier Darzacq, Beatrice Spiluttini Hebert
  • MOLECULAR TARGETS FOR THE PREVENTION AND/OR TREATMENT OF FIBROSIS, HYPERTROPHIC SCARS OR KELOIDS
    Publication number: 20180057819
    Abstract: The present invention relates to a therapeutic compound comprising: an agent that inhibits the activity of at least one gene selected from the group consisting of HIC1, FOXS1, CREB5, IRF7, POU2F2, STAT4, TCF4, and/or an agent that enhances the activity of at least one gene selected from the group consisting of MAF, MEOX2, SIX2.
    Type: Application
    Filed: November 10, 2017
    Publication date: March 1, 2018
    Inventors: Claire Dugast-Darzacq, Maïté Noizet, Xavier Darzacq
  • Molecular targets for the prevention and/or treatment of fibrosis, hypertrophic scars or keloids
    Patent number: 9840704
    Abstract: The present invention relates to a therapeutic compound comprising: an agent that inhibits the activity of at least one gene selected from the group consisting of HIC1, FOXS1, CREB5, IRF7, POU2F2, STAT4, TCF4, and/or an agent that enhances the activity of at least one gene selected from the group consisting of MAF, MEOX2, SIX2.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: December 12, 2017
    Assignees: Centre National de la Recherche Scientifique-CNRS CNRS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), URGO RECHERCHE INNOVATION ET DEVELOPPEMENT, UNIVERSITÉ PARIS DIDEROT—PARIS 7, ECOLE NORMALE SUPERIEURE
    Inventors: Claire Dugast-Darzacq, Maite Noizet, Xavier Darzacq
  • MOLECULAR TARGETS FOR THE TREATMENT OF WOUNDS, IN PARTICULAR CHRONIC WOUNDS
    Publication number: 20170281628
    Abstract: The present invention relates to a therapeutic compound comprising: an agent that inhibits the activity of at least one gene selected from the group consisting of MAF, MEOX2, SIX2 and homologues thereof having at least 50% identity with said genes and/or an agent that enhances the activity of at least one gene selected from the group consisting of CREBS, E2F1, EGR2, HIC1, IRF7, JUN, MYC, SRF, STAT4, TCF4, FOXS1, GLI1, SOX9 and homologues thereof having at least 50% identity with said gene for use in the treatment of wounds, preferably chronic wounds.
    Type: Application
    Filed: July 30, 2014
    Publication date: October 5, 2017
    Inventors: Claire Dugast-Darzacq, Maite Noizet, Xavier Darzacq, Beatrice Spiluttini Hebert
  • MOLECULAR TARGETS FOR THE PREVENTION AND/OR TREATMENT OF FIBROSIS, HYPERTROPHIC SCARS OR KELOIDS
    Publication number: 20160168565
    Abstract: The present invention relates to a therapeutic compound comprising: an agent that inhibits the activity of at least one gene selected from the group consisting of HIC1, FOXS1, CREB5, IRF7, POU2F2, STAT4, TCF4, and/or an agent that enhances the activity of at least one gene selected from the group consisting of MAF, MEOX2, SIX2.
    Type: Application
    Filed: July 30, 2014
    Publication date: June 16, 2016
    Applicant: Centre National de la Recherche Scienctifique-CNRS
    Inventors: Claire Dugast-Darzacq, Maite Noizet, Xavier Darzacq
  • METHOD AND KIT FOR THE CLASSIFICATION AND PROGNOSIS OF WOUNDS
    Publication number: 20150126447
    Abstract: The present invention relates to a method and kit for the classification and prognosis of wounds of mammalian, in particular in human. The method defines a molecular signature that enables one to characterize a pathological wound healing such as chronic or non-healing wound.
    Type: Application
    Filed: March 29, 2013
    Publication date: May 7, 2015
    Inventors: Claire Dugast Darzacq, Xavier Darzacq, Maite Noizet, Emilie Lagoutte, Hugues Roest Crollius, Marlene Gratigny, Marielle Bouschbacher
  • METHOD AND KIT FOR THE CLASSIFICATION AND PROGNOSIS OF TISSUE OR ORGAN FIBROSIS IN A REPARATIVE OR REACTIVE PROCESS
    Publication number: 20150087527
    Abstract: The invention relates to methods of diagnosis or prognosis of a tissue or organ fibrosis (e.g., skin fibrosis, hypertrophic scar or a keloid) in a reparative or reactive process comprising the step of determining the levels of expression of genes encoding different molecular markers in a sample of a tissue or organ from a mammalian, wherein different genes markers are studied.
    Type: Application
    Filed: March 29, 2013
    Publication date: March 26, 2015
    Inventors: Claire Dugast Darzacq, Xavier Darzacq, Maite Noizet, Emilie Lagoutte, Hugues Roest Crollius, Marlene Gratigny, Marielle Bouschbacher